Operator
Thank you for standing by, and welcome to the Mayne Pharma Group DistributeRx U.S. Launch Investor Presentation. [Operator Instructions]
I would now like to hand the conference over to Mr. Tom Duthy, Investor Relations. Please go ahead.
Thomas Duthy
Manager of Investor Relations
Thank you, Harmony, and thank you, everyone, for joining today’s call with Mayne Pharma and DistributeRx executives. It’s certainly an exciting period for Mayne Pharma with the launch of DistributeRx this week as announced on ASX yesterday, 10th of March 2026.
If I can have the next slide, please. This is our important disclaimer. We will be making forward-looking statements on today’s call. Investors are encouraged to read this disclaimer before making any form of investment decision.
Next slide, please. The agenda today is quite straightforward. We have 6 modules. I will shortly be introducing our esteemed speakers today who will then provide some background of Mayne Pharma who, for those investors who are less familiar with our story and our journey thus far into our DistributeRx launch this week. We will then provide a U.S. health care primer and what is the market need for a business like DistributeRx as part of overall Mayne Pharma’s journey through this disintermediation process that we’ve been undertaking for a number of years now, and that will be captured in Module 4 today. Finally, we will present the DistributeRx business model and the opportunity for DistributeRx moving forward as part of Mayne Pharma. And we’ll finish today with some investor Q&A. I might add that we have received a significant
